Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘AstraZeneca’

Will AstraZeneca’s SGLT2-favoring data win the class a shot at front-line diabetes use?

Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest.

Bron: FiercePharma Meer lezen »

AstraZeneca CEO warns of ‘substantial setback’ if new drug fails

AstraZeneca will face a “substantial setback” if its most ambitious foray into cutting edge immunotherapy falls flat, its chief executive Pascal Soriot has acknowledged. The eagerly awaited study into a new lung cancer drug is expected to produce its first results within weeks.

Bron: The Financial Times Meer lezen »

AstraZeneca sells migraine drug for up to $302 million

AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal. The British firm, which is betting on new drugs for cancer and other diseases to revive its fortunes, has sold or licensed out a raft of aging products recently.

Bron: Reuters Meer lezen »

AstraZeneca’s ASCO pledge? Be a better social media citizen

AstraZeneca changed its social media strategy for this year’s ASCO meeting, promising to do a better—and broader—job tweeting and posting from the conference. Inspired by suggestions and concerns from previous attendees, AstraZeneca has outlined a list of new-and-improved rules for its social media work during the annual American Society of Clinical Oncology meeting.

Bron: FiercePharma Meer lezen »

AstraZeneca phase IIIb/IV EXSCEL of Bydureon meets primary endpoint

AstraZeneca has announced top─line results from the phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once─weekly Bydureon (exenatide extended─release) versus placebo.

Bron: Pharma Biz Meer lezen »

Severe asthma drug shows AstraZeneca promise beyond cancer

AstraZeneca’s experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.

Bron: Reuters Meer lezen »

AZ launches lawsuit against former executive for defecting to GSK

AstraZeneca has launched a lawsuit against one of its former executives after he jumped ship to join rival pharma giant GlaxoSmithKline. Previously serving as AZ’s Executive Vice President for Europe, Luke Miels left in January and was appointed as the company’s President of Global Pharmaceuticals, succeeding Abbas Hussain.

Bron: Pharmafile Meer lezen »

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

AstraZeneca’s Imfinzi won its bladder cancer approval just last week—but it’s no longer the newest immuno-oncology med for the condition. Pfizer and Merck KGaA’s Bavencio (avelumab) nabbed its own accelerated FDA OK on Tuesday, with the advanced or metastatic urothelial carcinoma nod marking its second indication overall.

Bron: FiercePharma Meer lezen »

Bristol-Myers, AstraZeneca in legal hot seat over Onglyza heart failure warning

Last year, the FDA called for stronger heart-failure warnings on the label of AstraZeneca Type 2 diabetes med Onglyza. And now, AstraZeneca and former partner Bristol-Myers Squibb are being hit with 14 lawsuits related to the med’s heart-failure risks.

Bron: FiercePharma Meer lezen »

U.S. FDA approves AstraZeneca’s bladder cancer drug

U.S. regulators have approved AstraZeneca’s key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars.

Bron: Reuters Meer lezen »

« Oudere artikelen |